SUNNYVALE, Calif. , June 22, 2021 /PRNewswire/ -- Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021 . Ms. Winter , who previously served as the company's chief commercial officer and senior vice president of R&D and medical and
Revenue Expected to be Approximately $107.5 Million; Gross Orders Expected to be Approximately $67 Million Management Reiterates Guidance for FY2016 SUNNYVALE, Calif. , Jan. 11, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today preliminary product orders and revenues for the
Conference Call at 5:00 p.m. EST Today SUNNYVALE, Calif. , Jan. 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today preliminary results for the second quarter of fiscal 2013 that ended December 31, 2012 and updated guidance for fiscal 2013.
Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cash Equivalents & Investments Preliminary Revenue and Product Order Results for Fourth
SUNNYVALE, Calif. , Oct. 21, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), today announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021 . Accuray is currently finalizing its financial results for the first quarter of fiscal 2022.
New Service Helps Customers to Treat More Patients SUNNYVALE, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company will begin offering a treatment planning service to new and existing
SUNNYVALE, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Louis J. Lavigne, Jr. has been appointed Chairperson of the Company's Board of Directors, effective April 8, 2010.
Refinancing Significantly Reduces Interest Rate and Extends Maturity with Increased Operational Flexibility SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced it has entered into a new five-year $80 million term loan and $40 million revolving
Image-Guided, Intensity Modulated Radiation Therapy Added to UCSF's Suite of Treatment Options for Cancer Patients SUNNYVALE, Calif. , June 27, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that doctors at the University of
New CyberKnife Technologies Improve Treatment Times, Optimize Planning Objectives and Offer Increased Clinical Flexibility in Radiation Delivery SUNNYVALE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
